Li Weiqing,Dong Zilong,Chen Qian.Research advances in molecular subgroups and risk stratifications of medulloblastoma[J].Journal of Clinical Pediatric Surgery,2021,20(07):687-692.[doi:10.12260/lcxewkzz.2021.07.018]
髓母细胞瘤分子分型及危险分层的研究进展
- Title:
- Research advances in molecular subgroups and risk stratifications of medulloblastoma
- Keywords:
- Medulloblastoma; Molecular Subgroups; Risk Stratification; Prognosis
- 分类号:
- R730.56;R726.12
- 摘要:
- 近年来髓母细胞瘤的分子分型为疾病的预后提供了较为精准的信息，目前推荐用DNA甲基化图谱取代基因表达图谱作为髓母细胞瘤分子分型诊断的金标准。为进一步改善髓母细胞瘤患者预后，国内外学者重新定义了危险分层，更新了治疗策略，取得了良好的效果。本文通过文献复习，对髓母细胞瘤目前各分子亚型的特点及预后危险分层的研究进展作一综述。
- Abstract:
- In recent years,molecular subgrouping of medulloblastoma (MB) has provided relatively accurate information for its prognosis.Currently DNA methylation profiling is recommended for replacing gene expression analysis as a gold standard for determining MB subgroup status and substructure within subgroups.For further improving the prognosis of MB children,both domestic and foreign scholars redefined risk stratifications,updated treatment strategies and achieved excellent outcomes.This review summarized the characteristics of each molecular subgroup and its prognostic risk stratification.
参考文献/References:
1 Massimino M,Biassoni V,Gandola L,et al.Childhood medulloblastoma[J].Crit Rev Oncol Hematol,2016,105:35-51.DOI:10.1016/j.critrevonc.2016.05.012.
2 Louis DN,Perry A,Reifenberger G,et al.The 2016 World Health Organization Classification of Tumors of the Central Nervous System:a summary[J].Acta Neuropathol,2016,131(6):803-820.DOI:10.1007/s00401-016-1545-1.
3 Millard NE,De Braganca KC.Medulloblastoma[J].J Child Neurol,2016,31(12):1341-1353.DOI:10.1177/0883073815600866.
4 Ramaswamy V,Remke M,Adamski J,et al.Medulloblastoma subgroup-specific outcomes in irradiated children:who are the true high-risk patients?[J].Neuro Oncol,2016,18(2):291-297.DOI:10.1093/neuonc/nou357.
5 Miranda Kuzan-Fischer C,Juraschka K,Taylor MD.Medulloblastoma in the molecular era[J].J Korean Neurosurg Soc,2018,61(3):292-301.DOI:10.3340/jkns.2018.0028.
6 Sabel M,Fleischhack G,Tippelt S,et al.Relapse patterns and outcome after relapse in standard risk medulloblastoma:a report from the HIT-SIOP-PNET4 study[J].J Neurooncol,2016,129(3):515-524.DOI:10.1007/s11060-016-2202-1.
7 Skowron P,Ramaswamy V,Taylor MD.Genetic and molecular alterations across medulloblastoma subgroups[J].J Mol Med,2015,93(10):1075-1084.DOI:10.1007/s00109-015-1333-8.
8 Northcott PA,Korshunov A,Witt H,et al.Medulloblastoma comprises four distinct molecular variants[J].J Clin Oncol,2011,29(11):1408-1414.DOI:10.1200/JCO.2009.27.4324.
9 Northcott PA,Robinson GW,Kratz CP,et al.Medulloblastoma[J].Nat Rev Dis Primers,2019,5(1):11.DOI:10.1038/s41572-019-0063-6.
10 Schwalbe EC,Williamson D,Lindsey JC,et al.DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies[J].Acta Neuropathol,2013,125(3):359-371.DOI:10.1007/s00401-012-1077-2.
11 Hovestadt V,Remke M,Kool M,et al.Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays[J].Acta Neuropathol,2013,125(6):913-916.DOI:10.1007/s00401-013-1126-5.
12 Cavalli FMG,Remke M,Rampasek L,et al.Intertumoral heterogeneity within medulloblastoma subgroups[J].Cancer Cell,2017,31(6):737-754.DOI:10.1016/j.ccell.2017.05.005.
13 Schwalbe EC,Lindsey JC,Nakjang S,et al.Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma:a cohort study[J].Lancet Oncol,2017,18(7):958-971.DOI:10.1016/S1470-2045(17)30243-7.
14 Gibson P,Tong Y,Robinson G,et al.Subtypes of medulloblastoma have distinct developmental origins[J].Nature,2010,468(7327):1095-1099.DOI:10.1038/nature09587.
15 Taylor MD,Northcott PA,Korshunov A,et al.Molecular subgroups of medulloblastoma:the current consensus[J].Acta Neuropathol,2012,123(4):465-472.DOI:10.1007/s00401-011-0922-z.
16 Kool M,Korshunov A,Remke M,et al.Molecular subgroups of medulloblastoma:an international meta-analysis of transcriptome,genetic aberrations,and clinical data of WNT,SHH,Group 3,and Group 4 medulloblastomas[J].Acta Neuropathol,2012,123(4):473-484.DOI:10.1007/s00401-012-0958-8.
17 Phoenix TN,Patmore DM,Boop S,et al.Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype[J].Cancer Cell,2016,29(4):508-522.DOI:10.1016/j.ccell.2016.03.002.
18 Duchartre Y,Kim YM,Kahn M.The Wnt signaling pathway in cancer[J].Crit Rev Oncol Hematol,2016,99:141-149.DOI:10.1016/j.critrevonc.2015.12.005.
19 Waszak SM,Northcott PA,Buchhalter I,et al.Spectrum and prevalence of genetic predisposition in medulloblastoma:a retrospective genetic study and prospective validation in a clinical trial cohort[J].Lancet Oncol,2018,19(6):785-798.DOI:10.1016/S1470-2045(18)30242-0.
20 Villani A,Malkin D,Tabori U.Syndromes predisposing to pediatric central nervous system tumors:lessons learned and new promises[J].Curr Neurol Neurosci Rep,2012,12(2):153-164.DOI:10.1007/s11910-011-0244-5.
21 Qualman SJ,Bowen J,Erdman SH,et al.Molecular basis of the brain tumor-polyposis (Turcot) syndrome[J].Pediatr Dev Pathol,2003,6(6):574-576.DOI:10.1007/s10024-003-7068-5.
22 Clifford SC,Lusher ME,Lindsey JC,et al.Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis[J].Cell Cycle,2006,5(22):2666-2670.DOI:10.4161/cc.5.22.3446.
23 Northcott PA,Buchhalter I,Morrissy AS,et al.The whole-genome landscape of medulloblastoma subtypes[J].Nature,2017,547(7663):311-317.DOI:10.1038/nature22973.
24 Wang J,Garancher A,Ramaswamy V,et al.Medulloblastoma:from molecular subgroups to molecular targeted therapies[J].Annu Rev Neurosci,2018,41:207-232.DOI:10.1146/annurev-neuro-070815-013838.
25 Archer TC,Weeraratne SD,Pomeroy SL.Hedgehog-GLI pathway in medulloblastoma[J].J Clin Oncol,2012,30(17):2154-2156.DOI:10.1200/JCO.2011.41.1181.
26 Carballo GB,Honorato JR,de Lopes GPF,et al.A highlight on Sonic hedgehog pathway[J].Cell Commun Signal,2018,16(1):11.DOI:10.1186/s12964-018-0220-7.
27 Zhukova N,Ramaswamy V,Remke M,et al.Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma[J].J Clin Oncol,2013,31(23):2927-2935.DOI:10.1200/JCO.2012.48.5052.
28 Remke M,Ramaswamy V,Peacock J,et al.TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma[J].Acta Neuropathol,2013,126(6):917-929.DOI:10.1007/s00401-013-1198-2.
29 Kool M,Jones DT,J?ger N,et al.Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition[J].Cancer Cell,2014,25(3):393-405.DOI:10.1016/j.ccr.2014.02.004.
30 Northcott PA,Rutka JT,Taylor MD.Genomics of medulloblastoma:from Giemsa-banding to next-generation sequencing in 20 years[J].Neurosurg Focus,2010,28(1):E6.DOI:10.3171/2009.10.FOCUS09218.
31 Robinson GW,Rudneva VA,Buchhalter I,et al.Risk-adapted therapy for young children with medulloblastoma (SJYC07):therapeutic and molecular outcomes from a multicentre,phase 2 trial[J].Lancet Oncol,2018,19(6):768-784.DOI:10.1016/S1470-2045(18)30204-3.
32 Raybaud C,Ramaswamy V,Taylor MD,et al.Posterior fossa tumors in children:developmental anatomy and diagnostic imaging[J].Childs Nerv Syst,2015,31(10):1661-1676.DOI:10.1007/s00381-015-2834-z.
33 Kawauchi D,Robinson G,Uziel T,et al.A mouse model of the most aggressive subgroup of human medulloblastoma[J].Cancer Cell,2012,21(2):168-180.DOI:10.1016/j.ccr.2011.12.023.
34 Tseng YY,Moriarity BS,Gong W,et al.PVT1 dependence in cancer with MYC copy-number increase[J].Nature,2014,512(7512):82-86.DOI:10.1038/nature13311.
35 Northcott PA,Shih DJ,Peacock J,et al.Subgroup-specific structural variation across 1,000 medulloblastoma genomes[J].Nature,2012,488(7409):49-56.DOI:10.1038/nature11327.
36 Northcott PA,Lee C,Zichner T,et al.Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma[J].Nature,2014,511(7510):428-434.DOI:10.1038/nature13379.
37 Northcott PA,Jones DT,Kool M,et al.Medulloblastomics:the end of the beginning[J].Nat Rev Cancer,2012,12(12):818-834.DOI:10.1038/nrc3410.
38 Shih DJ,Northcott PA,Remke M,et al.Cytogenetic prognostication within medulloblastoma subgroups[J].J Clin Oncol,2014,32(9):886-896.DOI:10.1200/JCO.2013.50.9539.
39 Kunder R,Jalali R,Sridhar E,et al.Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas[J].Neuro-oncology,2013,15(12):1644-1651.DOI:10.1093/neu-onc/not123.
40 Lin CY,Erkek S,Tong Y,et al.Active medulloblastoma enhancers reveal subgroup-specific cellular origins[J].Nature,2016,530(7588):57-62.DOI:10.1038/nature16546.
41 Remke M,Hielscher T,Korshunov A,et al.FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma[J].J Clin Oncol,2011,29(29):3852-3861.DOI:10.1200/JCO.2011.36.2798.
42 孙晓非,甄子俊.儿童髓母细胞瘤多学科诊疗专家共识(CCCG-MB-2017)[J].中国小儿血液与肿瘤杂志,2018,23(4):169-174.DOI:10.3969/j.issn.1673-5323.2018.04.001. Sun XF,Zhen ZJ.Multidisciplinary expert consensus on the diagnosis and treatment of childhood medulloblastoma (CCCG-MB-2017)[J].J China Pediatr Blood Cancer,2018,23(4):169-174.DOI:10.3969/j.issn.1673-5323.2018.04.001.
43 Ramaswamy V,Remke M,Bouffet E,et al.Risk stratification of childhood medulloblastoma in the molecular era:the current consensus[J].Acta Neuropathol,2016,131(6):821-831.DOI:10.1007/s00401-016-1569-6.
相似文献/References:
[1]成英杰,单慈,石寒菡,等.MicroRNAs在肝母细胞瘤诊断、鉴别诊断及预后评估中的研究进展[J].临床小儿外科杂志,2019,18(08):660.[doi:10.3969/j.issn.1671-6353.2019.08.009]
Cheng Yingjie,Shan Ci,Shi Hanhan,et al.Research advances of MicroRNAs in the diagnosis,differential diagnosis and prognostic evaluation of hepatoblastoma[J].Journal of Clinical Pediatric Surgery,2019,18(07):660.[doi:10.3969/j.issn.1671-6353.2019.08.009]
[2]余建忠,施伟,赵瑞,等.儿童髓母细胞瘤的临床特点及预后相关因素分析[J].临床小儿外科杂志,2020,19(03):236.[doi:10.3969/j.issn.1671-6353.2020.03.009]
Yu Jianzhong,Shi Wei,Zhao Rui,et al.Clinical characteristics and prognostic factors of pediatric medulloblastoma[J].Journal of Clinical Pediatric Surgery,2020,19(07):236.[doi:10.3969/j.issn.1671-6353.2020.03.009]
备注/Memo
收稿日期:2020-05-15。
通讯作者:陈乾,Email:chenqian68@126.com